| (USD) | Dec 2023 | Q/Q |
|---|---|---|
| Revenue | 5.1MM | -6% |
| Gross Profit | 1.3MM | -1% |
| Cost Of Revenue | 3.8MM | -7% |
| Operating Income | -1MM | -15% |
| Operating Expenses | 2.3MM | -8% |
| Net Income | -1.1MM | +21% |
| R&D | 1.1MM | -5% |
| G&A | 523.3K | +2% |
| Marketing | 671.5K | -18% |
| Amortization | 4.8K | - |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
PORTLAND, Maine, April 09, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the first quarter of 2024, which ended March 31, 2024. Preliminary, Unaudited Total Sales Results: 20242023$ Increase % IncreaseDuring the T
ImmuCell Corporation (NASDAQ:ICCC) Q4 2023 Earnings Call Transcript February 28, 2024 ImmuCell Corporation isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning and welcome to the ImmuCell Corporation reports Fourth Quarter and Year Ended December 31, 2023 Unaudited Financial […]
PORTLAND, Maine, Feb. 27, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter and year ended December 31, 2023. Management’s Discussion: “Our unaudited, preliminary product sales for the fourth quarter of 2023 we
Conference Call Scheduled for Wednesday, February 28, 2024 at 9:00 AM ETPORTLAND, Maine, Feb. 16, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the quarter and year ended December 31, 2023 after the market closes on Tues
PORTLAND, Maine, Jan. 08, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the fourth quarter of 2023, which ended December 31, 2023. Preliminary, Unaudited Total Sales Results: 20232022$ Increase($ Decrease)% Increa
ImmuCell Corporation (NASDAQ:ICCC) Q3 2023 Earnings Call Transcript November 14, 2023 Operator: Good day, everyone, and welcome to the ImmuCell Corporation’s Third Quarter 2023 Financial Results Conference Call. [Operator Instructions] Please note this event is being recorded. And now I would like to turn the conference over to Joe Diaz. Please go ahead. Joe Diaz: […]
PORTLAND, Maine, Nov. 13, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended September 30, 2023. Management’s Discussion: “Our unaudited, preliminary product sales for the third quarter of 2023 were first
Conference Call Scheduled for Tuesday, November 14, 2023 at 9:00 AM ETPORTLAND, Maine, Nov. 07, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the quarter ended September 30, 2023 after the market closes on Monday, Novemb
PORTLAND, Maine, Oct. 05, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the third quarter of 2023, which ended September 30, 2023. Preliminary, Unaudited Total Sales Results: 20232022$ Increase ($ Decrease) % Incr
PORTLAND, Maine, Aug. 29, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, announced today that it recently submitted the Chemistry, Manufacturing and Controls (CMC) Technical Section for Re-Tain® to the FDA. On August 10, 2023, the Company issued a disclosure stating that